Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearin
Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.
A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).
Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.